USSTOCK.TODAY
Pre-Market
Log in Sign up

Eli Lilly raises revenue guidance and Viking Therapeutics competes in obesity treatment market

The Motley Fool +1 · ·by G4L

VKTX
VKTX Viking Therapeutics Inc
$27.58 -3.02%
View chart & analysis →
  1. 1Eli Lilly recorded $24.4 billion in revenue for the third quarter.
  2. 2Eli Lilly achieved a 39% year-over-year revenue growth rate in the third quarter.
  3. 3Viking Therapeutics is conducting a Phase 3 clinical study for a subcutaneous version of VK2735.

So what's the key point?

Eli Lilly's revenue grew by 39% compared to last year in the third quarter. Viking Therapeutics is also competing by testing a new injectable obesity treatment.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Viking Therapeutics seeks market expansion by starting Phase 3 clinical trials for oral VK2735 The Motley Fool +1 · 51m agoEli Lilly widens market cap gap with Novo Nordisk in obesity treatment competition The Motley Fool +7 · 3d agoViking Therapeutics shares fall approximately 23% below capital increase issue price The Motley Fool +1 · Nov 4
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news